We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




fMRI Could Help Identify New Painkillers

By MedImaging International staff writers
Posted on 10 Feb 2016
Print article
Measuring the brain's neural response to pain using functional magnetic resonance imaging (fMRI) may be a viable tool for evaluating the effectiveness of new pain medications, according to a new study.

Researchers at John Radcliffe Hospital (Oxford, United Kingdom) and Oxford University (United Kingdom) conducted a double-blind, randomized study in 24 healthy volunteers on three separate occasions to assess the use of fMRI in obtaining objective outcome measures of drug differentiation. To induce pain, the researchers used capsaicin cream, a topical irritant often used to produce similar characteristics of neuropathic pain on subjects' skin.

Prior to capsaicin cream application, the subjects either received a single dose of gabapentin, which is considered effective and a first line treatment for neuropathic pain; ibuprofen, which is generally not considered an effective treatment for the condition; or a placebo. The researchers then assessed the effect the drugs or placebo had on the brain's neural response to pain using fMRI, in addition to patient-reported pain relief.

The results showed that neural activity was significantly reduced in the subjects who received gabapentin, even with extremely low subject numbers, highlighting the potential for fMRI to make a drug's effect clear in small cohorts, such as during the early stages of human drug development. This ability could provide a much-needed objective method to collect data that could prevent premature discarding of potentially beneficial therapies. The study was published in the January 2106 issue of Anesthesiology.

“Chronic pain is a very common condition. Even the most effective pain medications currently available only provide adequate pain relief, defined as a 50% reduction in pain, in one out of four patients, while some drugs, such as opioids, have significant side effects, including dependence and overuse,” said lead author Vishvarani Wanigasekera, MD, of the University of Oxford. “We believe that neuroimaging techniques, such as fMRI, can provide objective evidence that can be used as outcome measures in early drug development to enhance the efficiency of the drug development process.”

Patient-reported pain relief is the primary outcome measure used in current drug development studies to assess whether medication is effective or not. However, due to their subjective and context-dependent nature, self-reported pain perception and relief are subject to many influences. Due to the low subject population, researchers can also easily miss effective compounds that might work well in the population at large.

Related Links:

John Radcliffe Hospital
Oxford University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Doppler System
Doppler BT-200
New
PACS Workstation
CHILI Web Viewer
Radiology Software
MSK Radiology

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.